SCHEMBL5078702

SCHEMBL5078702

BrNCCC(Oc1cccc2ccccc12)c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 18/20 0.75
SLC6A2 P23975 16/20 0.75
CYP1A2 P05177 4/20 0.50
CYP3A4 P08684 4/20 0.50
CYP2D6 P10635 4/20 0.50
SLC6A3 Q01959 3/20 0.50
KMT2A Q03164 3/20 0.50
ADRA2B P18089 2/20 0.50
HTR2A P28223 2/20 0.50
HTR2C P28335 2/20 0.50
CYP2C19 P33261 2/20 0.50
HRH1 P35367 2/20 0.50
OPRM1 P35372 2/20 0.50
DRD3 P35462 2/20 0.50
OPRK1 P41145 2/20 0.50
HTR2B P41595 2/20 0.50
KCNH2 Q12809 2/20 0.50
MLNR O43193 1/20 0.50
CACNA1F O60840 1/20 0.50
ADRB1 P08588 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2722680 0.86 SLC6A4 (1.00) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL8285421 0.82 SLC6A4 (0.69) SLC6A4SLC6A2CYP1A2SLC6A3KMT2A
SCHEMBL541162 0.81 SLC6A2 (0.68) SLC6A4SLC6A2CYP2D6SLC6A3
SCHEMBL28017684 0.81 SLC6A2 (0.68) SLC6A4SLC6A2CYP2D6SLC6A3
Bromide SCHEMBL6903611 0.79 SLC6A2 (0.66) SLC6A4SLC6A2CYP2D6SLC6A3
SCHEMBL27906357 0.79 SLC6A4 (0.65) SLC6A4SLC6A2KMT2AHTR1A
SCHEMBL5471086 0.78 SLC6A4 (0.64) SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6
SCHEMBL28037844 0.77 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3
SCHEMBL9995405 0.77 SLC6A4 (0.67) SLC6A4SLC6A2HRH3
SCHEMBL17278119 0.77 SLC6A2 (0.63) SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008133884-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-11-06 WO disclosed
EP-1425002-A1 ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER Ramot at Tel Aviv University Ltd. (IL) 2004-06-09 EP disclosed
WO-2003022258-A1 ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2003-03-20 WO disclosed